망막분지정맥폐쇄에 의한 황반부종에서 유리체강내 베바시주맙 주입술의 장기효과

Long-Term Effects of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion

Purpose: To report the long term effects of intravitreal bevacizumab injection (IVAI) for the treatment of macular edema due to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 47 consecutive patients (47 eyes) whose visual acuity under 20/40 and macular thickness over 250 μm from BRVO received IVAI (1.25 mg). All patients were observed over 12 months. The patients were classified into three groups: one, resolved macular edema after first injection, second, persistant, third, recurrant. At 12 months after injection, best corrected visual acuity (BCVA) and central macular thickness (CMT) were compared with one another. Results: Comparing with baseline BCVA (0.96 ± 0.32, 1.13 ± 0.42, 0.85 ± 0.24 log MAR unit), the mean at 12 months was significantly increased (0.50 ± 0.30, 0.76 ± 0.51, 0.55 ± 0.35) in each group. The mean CMT at baseline was 510.84 (± 171.07), 538.5 (± 216.87), 522.6 (± 101.82) μm decreased to 211.58 (± 42.74), 232 (± 132.68), 270.6 (± 85.27). Conclusions: IVAI was a result of significant decrease of CMT with improvement of BCVA in patients with BRVO after a follow- up of 12 months. J Korean Ophthalmol Soc 2012;53(2):283-290